Pharmacokinetic marker genes of patients with severe schizophrenia resistant to antipsychotic therapy

The response to drug therapy is determined by the genetic characteristics of pharmacokinetic and pharmacodynamic processes in the human body. The study of the relationship between genetic factors and the resistance of patients with severe outcome is necessary to understand the causes of the formation of this endophenotype of schizophrenia. Our analysis showed a more frequent combination of a severe outcome of schizophrenia with alleles of genes that control the peripheral metabolism of xenobiotics and cause the pharmacokinetic processes of antipsychotic therapy.

1. Volavka, J. Very long-term outcome of schizophrenia / J. Volavka, J. Vevera // Int. J. Clin. Pract, 2018. – Vol. 72 (7).

2. Davis, L. Economics and schizophrenia: the real cost / L. Davis, M. Drummond // Br. J. Psychiatry, 1994. – Vol. 25. – P. 18–21.

3. Characteristics of very poor outcome schizophrenia / R. Keefe [et al.] // American Journal of Psychiatry, 1987. – Vol. 144 (889). – P. 895.

4. Kraepelinian schizophrenia: A subgroup of schizophrenia? / R. Keefe [et al.] // Psychopharmacological Bulletin, 1988. – Vol. 24 (56). – R. 61.

5. Premorbidsociosexual functioning and long–term outcome in schizophrenia / R. Keefe [et al.] // American Journal of Psychiatry, 1989. – Vol. 146 (206). – R. 211.

6. The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project / G. Blokland [et al.] //Schizophrenia Research., 2018. – Vol. 195 (306). – R. 317.

7. Gaebel, W. New concepts for predicting the outcome in neuroleptic treatment / W. Gaebel // Eur. Arch. Psychiatry Clin. Neurosci, 2009. – Vol. 259 (1). – P. 42.

8. Degenhardt, F. Update on the genetic architecture of schizophrenia. / F. Degenhardt // Medizinische genetic, 2020. – Vol. 32 (1). – P. 19–24.

9. De Leon, J. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness / J. De Leon [et al.] // J ClinPsychopharmacol, 2005. – Vol. 25 (5). – P. 448–456.

10. De Luca, V. MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis / V. DeLuca [et al.] // Schizophr Res, 2009. – Vol. 110 (1–3). – P. 200–201.

11. Foster, A. Pharmacogenetics and schizophrenia / A. Foster , D.D. Miller, P.F. Buckley // PsychiatrClinNorth Am, 2007. – Vol. 30(3). – P. 417–35.

12. Patsopoulos, N.A. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis / N.A. Patsopoulos, E.E. Ntzani, E. Zintzaras, J.P. Ioannidis // PharmacogenetGenomics, 2005. – Vol. 15(3). – P. 151–158.

13. D2-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D / E. Daskalopoulos [et al.] // Mol. Pharmacol, 2012. – Vol. 82 (4). – P. 668–678.

14. Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6 / S. Thümmler [et al.] // Front Psychiatry, 2018. – Vol. 24 (9). – P. 2.

15. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study / C. Kobylecki [et al.] // Ther Drug Monit, 2008. – Vol. 30 (3). – P. 265–270.

16. Methylenetetrahydrofolate reductase gene variants and antipsychotic–induced weight gain and metabolic disturbances / A. Kao [et al.] // J. Psychiatr. Res, 2014. – Vol. 54. – P. 36–42.

17. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic–induced weight gain in female schizophrenic patients / R. Kuzman [et al.] // Psychiatry Res, 2008. – Vol. 160 (3). – P. 308–315.

18. Youssef, D. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids / D. Youssef, T. Attia, A. El-Shal, F. Abduelometty // Gene, 2013. – Vol. 10 (530). – P. 201–207.